About this condition
CLL — Chronic Lymphocytic Leukemia Genetic Risk
CLL is the most common adult leukemia in Western countries, with approximately 20,000 new US cases annually. CLL has the strongest familial clustering of any leukemia — first-degree relatives have approximately 6-9x increased risk. GWAS have identified >40 susceptibility loci contributing to CLL predisposition, with the strongest signals at 2q13, 6p25.3, 11q24.1, and 15q21.3.
TP53 status is the single most important molecular determinant in CLL treatment selection. TP53 deletion (del17p) or TP53 mutation identifies patients who do NOT respond to chemoimmunotherapy (fludarabine-rituximab) — requiring BTK inhibitor-based therapy (ibrutinib, acalabrutinib, zanubrutinib) or venetoclax-based regimens. Missing TP53 status leads to chemoimmunotherapy failure in ~10% of CLL patients.
BTK inhibitors have transformed CLL outcomes: ibrutinib (first-in-class, 2014), acalabrutinib (next-generation, improved safety), and zanubrutinib (most selective, fewest off-target effects). Venetoclax (BCL2 inhibitor) produces deep responses including MRD negativity. These targeted therapies have made CLL one of the most treatable malignancies.
TP53 deletion/mutation in CLL means chemoimmunotherapy will FAIL. BTK inhibitors or venetoclax are required. Missing TP53 testing wastes time on ineffective treatment while the disease progresses.
- Gene locus
- TP53 (17p13.1), Multiple GWAS loci (2q13, 6p25.3, 11q24.1, 15q21.3)
